FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161769425> ?p ?o ?g. }

• W2161769425 endingPage "729" @default.
• W2161769425 startingPage "726" @default.
• W2161769425 abstract "Background Hidradenitis suppurativa (HS) is a chronic suppurative condition which is poorly responsive to treatment and is characterized by significant morbidity. Successful treatment of HS in patients treated with infliximab for concomitant Crohn's disease has been reported. More recent reports of positive responses to infliximab [an antitumour necrosis factor (TNF)-α agent] in patients who have HS but not Crohn's disease are encouraging. Objectives TNF-α is implicated in many inflammatory disorders and we wished to determine the efficacy of subcutaneous etanercept, a competitive inhibitor of TNF-α in the control of HS symptoms. Methods We commenced six patients with severe, recalcitrant HS on etanercept (25 mg subcutaneously twice weekly in all cases). All patients had a normal chest X-ray and negative purified protein derivative test prior to treatment and were closely monitored throughout the treatment period for signs of infection. Patients self-assessed their disease activity and completed Dermatology Life Quality Index (DLQI) questionnaires immediately before the introduction of therapy and 24 weeks later in the case of four patients, and 12 weeks later in the case of two others. All patients were asked to estimate the time lapse between commencement of treatment and initial response. Results Treatment was well tolerated by all patients with no reported adverse reactions. A marked reduction in self-reported disease activity (mean reduction of 61% at 24 weeks), in DLQI scores (mean reduction of 64% at 24 weeks) and in relapse rates occurred. All patients rated etanercept as their most effective treatment to date. Conclusions Our results show the effectiveness of etanercept in this group of patients with particularly challenging disease. Etanercept, unlike infliximab, may be administered subcutaneously, rendering costly day-case admissions unnecessary." @default.
• W2161769425 created "2016-06-24" @default.
• W2161769425 creator A5030872896 @default.
• W2161769425 creator A5048714074 @default.
• W2161769425 date "2006-01-16" @default.
• W2161769425 modified "2023-10-18" @default.
• W2161769425 title "Etanercept: effective in the management of hidradenitis suppurativa" @default.
• W2161769425 cites W1498614151 @default.
• W2161769425 cites W1985885066 @default.
• W2161769425 cites W1999378785 @default.
• W2161769425 cites W2000568465 @default.
• W2161769425 cites W2006434929 @default.
• W2161769425 cites W2012847560 @default.
• W2161769425 cites W2015963927 @default.
• W2161769425 cites W2023607778 @default.
• W2161769425 cites W2026701360 @default.
• W2161769425 cites W2045789990 @default.
• W2161769425 cites W2045935970 @default.
• W2161769425 cites W2060196667 @default.
• W2161769425 cites W2081833623 @default.
• W2161769425 cites W2091177739 @default.
• W2161769425 cites W2091442391 @default.
• W2161769425 cites W2096991001 @default.
• W2161769425 cites W2098767548 @default.
• W2161769425 cites W2112340015 @default.
• W2161769425 cites W2128208773 @default.
• W2161769425 cites W2128583237 @default.
• W2161769425 cites W2151772152 @default.
• W2161769425 cites W2155837342 @default.
• W2161769425 cites W2158335096 @default.
• W2161769425 cites W2158688016 @default.
• W2161769425 cites W2172208853 @default.
• W2161769425 cites W4211107250 @default.
• W2161769425 cites W83676127 @default.
• W2161769425 doi "https://doi.org/10.1111/j.1365-2133.2005.07067.x" @default.
• W2161769425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16536817" @default.
• W2161769425 hasPublicationYear "2006" @default.
• W2161769425 type Work @default.
• W2161769425 sameAs 2161769425 @default.
• W2161769425 citedByCount "143" @default.
• W2161769425 countsByYear W21617694252012 @default.
• W2161769425 countsByYear W21617694252013 @default.
• W2161769425 countsByYear W21617694252014 @default.
• W2161769425 countsByYear W21617694252015 @default.
• W2161769425 countsByYear W21617694252017 @default.
• W2161769425 countsByYear W21617694252018 @default.
• W2161769425 countsByYear W21617694252019 @default.
• W2161769425 countsByYear W21617694252020 @default.
• W2161769425 countsByYear W21617694252021 @default.
• W2161769425 countsByYear W21617694252022 @default.
• W2161769425 countsByYear W21617694252023 @default.
• W2161769425 crossrefType "journal-article" @default.
• W2161769425 hasAuthorship W2161769425A5030872896 @default.
• W2161769425 hasAuthorship W2161769425A5048714074 @default.
• W2161769425 hasConcept C126322002 @default.
• W2161769425 hasConcept C141071460 @default.
• W2161769425 hasConcept C159110408 @default.
• W2161769425 hasConcept C16005928 @default.
• W2161769425 hasConcept C17991360 @default.
• W2161769425 hasConcept C197934379 @default.
• W2161769425 hasConcept C2776002364 @default.
• W2161769425 hasConcept C2776173921 @default.
• W2161769425 hasConcept C2777138892 @default.
• W2161769425 hasConcept C2777226972 @default.
• W2161769425 hasConcept C2779134260 @default.
• W2161769425 hasConcept C2779384505 @default.
• W2161769425 hasConcept C2779951463 @default.
• W2161769425 hasConcept C2780132546 @default.
• W2161769425 hasConcept C71924100 @default.
• W2161769425 hasConcept C90924648 @default.
• W2161769425 hasConceptScore W2161769425C126322002 @default.
• W2161769425 hasConceptScore W2161769425C141071460 @default.
• W2161769425 hasConceptScore W2161769425C159110408 @default.
• W2161769425 hasConceptScore W2161769425C16005928 @default.
• W2161769425 hasConceptScore W2161769425C17991360 @default.
• W2161769425 hasConceptScore W2161769425C197934379 @default.
• W2161769425 hasConceptScore W2161769425C2776002364 @default.
• W2161769425 hasConceptScore W2161769425C2776173921 @default.
• W2161769425 hasConceptScore W2161769425C2777138892 @default.
• W2161769425 hasConceptScore W2161769425C2777226972 @default.
• W2161769425 hasConceptScore W2161769425C2779134260 @default.
• W2161769425 hasConceptScore W2161769425C2779384505 @default.
• W2161769425 hasConceptScore W2161769425C2779951463 @default.
• W2161769425 hasConceptScore W2161769425C2780132546 @default.
• W2161769425 hasConceptScore W2161769425C71924100 @default.
• W2161769425 hasConceptScore W2161769425C90924648 @default.
• W2161769425 hasIssue "4" @default.
• W2161769425 hasLocation W21617694251 @default.
• W2161769425 hasLocation W21617694252 @default.
• W2161769425 hasOpenAccess W2161769425 @default.
• W2161769425 hasPrimaryLocation W21617694251 @default.
• W2161769425 hasRelatedWork W1973470095 @default.
• W2161769425 hasRelatedWork W2011274987 @default.
• W2161769425 hasRelatedWork W2030481979 @default.
• W2161769425 hasRelatedWork W2064645888 @default.
• W2161769425 hasRelatedWork W2141308695 @default.
• W2161769425 hasRelatedWork W2163737309 @default.
• W2161769425 hasRelatedWork W2800869485 @default.

• next